In ovarian cancer, BRCA1/BRCA2 HRD detection is concordant across 20 assays, but non-BRCA HRD varies (correlation 0.4–0.9), risking 20% missed cases. This evidence concerns the gene BRCA2 and ovarian carcinoma.